All Oncology News

A bill to repeal the SGR formula garnered critical support with a vote by the House of Representatives.

In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

In an interview with OncLive, Don Dizon, MD, explains the advantages of IP therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Two studies investigating enzalutamide in men with early stage metastatic castration-resistant prostate cancer further confirmed the overall survival and progression-free survival benefit of the agent over placebo.

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

OncLive and the University of Cincinnati Cancer Institute announced today that they've joined forces to share news about the Institute's latest developments through OncLive's Strategic Alliance Partnership program.

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

Progression on treatment with ibrutinib in patients with chronic lymphocytic leukemia was associated with pretreatment BCL6 abnormalities, acquired mutations in BTK and PLCG2, and complex karyotypes.

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

Leaders in Congress today reached a bipartisan, bicameral deal to permanently repeal and replace Medicare's sustainable growth-rate formula for paying physicians.

In an interview with OncLive, Randy Gascoyne, MD, explains how predictive biomarkers can help oncologists select the right therapies for their patients and why they are the critical next step to improving outcomes in NHL.

OncLive and Georgetown Lombardi Comprehensive Cancer Center have teamed up to highlight leading-edge cancer research and innovative cancer treatment programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

In the phase III BEACON trial, etirinotecan pegol missed the primary endpoint of significantly extending overall survival versus physician's choice of therapy.

Patients with NRAS-mutated melanoma had better responses and improved treatment outcomes compared with those who did not harbor the mutation, according to a recent retrospective study.

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.

To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.

Inhibiting EZH2 may improve outcomes in patients with clear cell ovarian carcinoma who harbor a ARID1A mutation.

The phase III HELIOS study examining ibrutinib in combination with bendamustine and rituximab has been unblinded following the demonstration of a significant extension in progression-free survival in patients with CLL or SLL.

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

Patients with cancer are living longer thanks to new treatments, but the US oncology care system is burdened by growing administrative responsibilities, difficulties obtaining payment, and runaway costs.

A new report has called for broad changes in the way drugs are priced in the United States, saying the law of supply and demand is not doing an effective job of bringing the cost of cancer drugs down to a level comparable with other countries.

What if a negative study had been made available through a secure online registry where patients could sign up, with the assistance of their own oncologists?

OncLive spoke with Sanaz Memarzadeh, MD, on why ovarian and endometrial cancers are so challenging to treat, and what future research is needed to better understand these diseases.

Josh D. Lauring, MD, PhD, of Johns Hopkins Medicine, discusses efforts to develop breast cancer therapies by targeting the PI3K pathway.

A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).